Gene therapy takes on rare eye disease in Second-Eye trial

NCT ID NCT07586306

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is for people with Bietti's crystalline dystrophy, a rare genetic eye disease that causes vision loss. They have already received the gene therapy VGR-R01 in one eye. Now, researchers want to test if giving the same treatment to the other eye is safe and can improve vision. About 15 participants will be followed for side effects and changes in eyesight.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BIETTI CRYSTALLINE DYSTROPHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Bietti crystalline corneoretinal dystrophy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Beijing Tongren Hospital

    Beijing, Beijing Municipality, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Shanghai General Hospital (Shanghai First People's Hospital)

    Shanghai, Shanghai Municipality, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••